Keto-bridged dual triazole-linked benzenesulfonamides as potent carbonic anhydrase and cathepsin B inhibitors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 2. Ansari MA, Nadeem A, Alshammari MA et al. Cathepsin B inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental autoimmune encephalomyelitis. Exp. Neurol. 351, 113997 (2022).
  Medline CASGoogle Scholar
• 3. Kumar A, Siwach K, Supuran CT, Sharma PK. A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors. Bioorg. Chem. 126, 105920 (2022). •• Important review on inhibitors of tumor-associated carbonic anhydrase isoforms.
  Medline CASGoogle Scholar
• 4. Angeli A, Micheli L, Carta F et al. First-in-class dual hybrid carbonic anhydrase inhibitors and transient receptor potential vanilloid 1 agonists revert oxaliplatin-induced neuropathy. J. Med. Chem. 66(2), 1616–1633 (2023).
  Medline CASGoogle Scholar
• 5. Chhikara B, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem. Biol. Lett. 10, 451 (2022).
  Google Scholar
• 6. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev. 26(2), 223 (2007).
  Medline CASGoogle Scholar
• 7. Shaik Mahammad G, Kavyaraj B, Andrea A et al. Synthesis and biological evaluation of new 3-substituted coumarin derivatives as selective inhibitors of human carbonic anhydrase IX and XII. J. Enzyme Inhib. Med. Chem. 38(1), 2185760 (2023).
  MedlineGoogle Scholar
• 8. Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 7(3), 48 (2017). •• Important review on inhibitors of tumor-associated carbonic anhydrase isoforms.
  MedlineGoogle Scholar
• 9. Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin. Investig. Drugs 27(12), 963–970 (2018).
  Medline CASGoogle Scholar
• 10. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 27(6), 759–772 (2012).
  Medline CASGoogle Scholar
• 11. Geers C, Gros G. Carbon dioxide transport and carbonic anhydrase in blood and muscle. Physiol. Rev. 80(2), 681–715 (2000).
  Medline CASGoogle Scholar
• 12. Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin. Drug Discov. 14(11), 1175–1197 (2019).
  Medline CASGoogle Scholar
• 13. Angeli A, Supuran CT. Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications. J. Enzyme Inhib. Med. Chem. 38(1), 2166503 (2023).
  MedlineGoogle Scholar
• 14. Supuran CT. Carbonic anhydrase activators. Future Med. Chem. 10(5), 561–573 (2018).
  CASGoogle Scholar
• 15. Siklos M, Benaissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm. Sin. B 5(6), 506–519 (2015).
  MedlineGoogle Scholar
• 16. Saroha B, Kumar G, Kumar S et al. Novel 1,2,3-triazole-aurone hybrids as cathepsin B inhibitors: one-pot synthesis, anti-proliferative, and drug modeling studies. Eur. J. Med. Chem. Rep. 5, 100056 (2022).
  CASGoogle Scholar
• 17. Puente XS, Sánchez LM, Overall CM, López-Otín C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4(7), 544–558 (2003).
  Medline CASGoogle Scholar
• 18. Turk V, Stoka V, Vasiljeva O et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta. 1824(1), 68–88 (2012).
  Medline CASGoogle Scholar
• 19. Sulpizio S, Franceschini N, Piattelli A, Di Sebastiano P, Innocenti P, Selvaggi F. Cathepsins and pancreatic cancer: the 2012 update. Pancreatology 12(5), 395–401 (2012).
  Medline CASGoogle Scholar
• 20. Frlan R, Gobec S. Inhibitors of cathepsin B. Curr. Med. Chem. 13(19), 2309–2327 (2006).
  Medline CASGoogle Scholar
• 21. Kos J, Mitrović A, Mirković B. The current stage of cathepsin B inhibitors as potential anticancer agents. Future Med. Chem. 6(11), 1355–1371 (2014).
  CASGoogle Scholar
• 22. Gondi CS, Rao JS. Cathepsin B as a cancer target. Expert Opin. Ther. Targets 17(3), 281–291 (2013). • Important article on cathepsin B as a cancer target.
  Medline CASGoogle Scholar
• 23. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res. 61(8), 3493–3500 (2001).
  Medline CASGoogle Scholar
• 24. Gulçin İ, Taslimi P. Sulfonamide inhibitors: a patent review 2013–present. Expert Opin. Ther. Pat. 28(7), 541–549 (2018). •• Important review on sulfonamide-based carbonic anhydrase inhibitors.
  Medline CASGoogle Scholar
• 25. Culletta G, Tutone M, Zappalà M, Almerico AM. Sulfonamide moiety as ‘molecular chimera’ in the design of new drugs. Curr. Med. Chem. 30(2), 128–163 (2023).
  Medline CASGoogle Scholar
• 26. Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med. Chem. 6(10), 1149–1165 (2014). •• Important review on sulfonamide-based carbonic anhydrase inhibitors.
  CASGoogle Scholar
• 27. Pichake J, Kharkar PS, Ceruso M, Supuran CT, Toraskar MP. Carbonic anhydrase inhibitors: design, synthesis, and biological evaluation of novel sulfonyl semicarbazide derivatives. ACS Med. Chem. Lett. 5(7), 793–796 (2014).
  Medline CASGoogle Scholar
• 28. Kciuk M, Gielecińska A, Mujwar S et al. Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. J. Enzyme Inhib. Med. Chem. 37(1), 1278–1298 (2022).
  Medline CASGoogle Scholar
• 29. Eloranta K, Pihlajoki M, Liljeström E et al. SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration. Front. Oncol. 13, 1118268 (2023).
  Medline CASGoogle Scholar
• 30. Supuran CT, Casini A, Scozzafava A. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med. Res. Rev. 23(5), 535–558 (2003).
  Medline CASGoogle Scholar
• 31. Yadav P, Kaushik CP, Yadav A, Yadav J, Singh D. Piperazine-1,2,3-triazole scaffolds: design, synthesis, anticancer and antimicrobial evaluation. Future Med. Chem. 15(8), 679–697 (2023).
  CASGoogle Scholar
• 32. Popov AB, Macan AM, Jakopec S et al. Green solvent-free synthesis of new N-heterocycle-L-ascorbic acid hybrids and their antiproliferative evaluation. Future Med. Chem. 14(16), 1187–1202 (2022).
  CASGoogle Scholar
• 33. Singh A, Viljoen A, Kremer L, Kumar V. Azide–alkyne cycloaddition en route to 4-aminoquinoline–ferrocenylchalcone conjugates: synthesis and anti-TB evaluation. Future Med. Chem. 9(15), 1701–1708 (2017).
  CASGoogle Scholar
• 34. Sharma K, Tittal RK, Lal K, Mathpati RS. Fluorescent 7-azaindole N-linked 1,2,3-triazole: synthesis and study of antimicrobial, molecular docking, ADME and DFT properties. New J. Chem. 47(19), 9077–9086 (2023).
  CASGoogle Scholar
• 35. Kumar A, Siwach K, Rom T et al. Tail-approach based design and synthesis of arylthiazolylhydrazono-1,2,3-triazoles incorporating sulfanilamide and metanilamide as human carbonic anhydrase I, II, IV and IX inhibitors. Bioorg. Chem. 123, 105764 (2022).
  Medline CASGoogle Scholar
• 36. Kumar R, Kumar A, Ram S et al. Novel benzenesulfonamide‐bearing pyrazoles and 1,2,4‐thiadiazoles as selective carbonic anhydrase inhibitors. Arch. Pharm. 355(1), 2100241 (2022).
  CASGoogle Scholar
• 37. Sharma V, Kumar R, Angeli A, Supuran CT, Sharma PK. Benzenesulfonamides with trisubstituted triazole motif as selective carbonic anhydrase I, II, IV, and IX inhibitors. Arch. Pharm. 356(1), 2200391 (2023).
  CASGoogle Scholar
• 38. Vats L, Kumar R, Bua S et al. Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors. Eur. J. Med. Chem. 183, 111698 (2019).
  MedlineGoogle Scholar
• 39. Kumar R, Vats L, Bua S, Supuran CT, Sharma PK. Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors. Eur. J. Med. Chem. 155, 545–551 (2018).
  Medline CASGoogle Scholar
• 40. Vats L, Siwach K, Angeli A et al. Tail approach synthesis of triazolylthiazolotriazole bearing benzenesulfonamides as carbonic anhydrase inhibitors capable of inducing apoptosis. Arch. Pharm. 356(2), 2200439 (2023). • Important article on carbonic anhydrase inhibitors endowed with apoptosis induction properties.
  CASGoogle Scholar
• 41. Siwach K, Kumar A, Panchal H et al. Selective inhibition of carbonic anhydrase IX by sulphonylated 1, 2, 3-triazole incorporated benzenesulphonamides capable of inducing apoptosis. J. Enzyme Inhib. Med. Chem. 37(1), 1454–1463 (2022).
  Medline CASGoogle Scholar
• 42. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 246(8), 2561–2573 (1971).
  Medline CASGoogle Scholar
• 43. Vullo D, Del Prete S, Nocentini A et al. Dithiocarbamates effectively inhibit the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa. Bioorg. Med. Chem. 25(3), 1260–1265 (2017).
  Medline CASGoogle Scholar
• 44. Fares M, Eladwy RA, Nocentini A et al. Synthesis of bulky-tailed sulfonamides incorporating pyrido [2, 3-d] [1,2,4] triazolo [4, 3-a] pyrimidin-1 (5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects. Bioorg. Med. Chem. 25(7), 2210–2217 (2017).
  Medline CASGoogle Scholar
• 45. Raghav N, Singh M, Garg S, Kaur R, Jangra S, Ravish I. Ion exchangers: a useful tool for separation and simultaneous purification of lysosomal cysteine proteinases, cathepsins B, H and L. Int. J. Pharm. Sci. Res. 6, 2944–2949 (2015).
  CASGoogle Scholar
• 46. Garg S, Raghav N. 2, 5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L. Bioorg. Chem. 67, 64–74 (2016).
  Medline CASGoogle Scholar
• 47. Raghav N, Singh M. Design, synthesis and docking studies of bischalcones based quinazoline-2 (1H)-ones and quinazoline-2 (1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H. Eur. J. Pharm. Sci. 54, 28–39 (2014).
  Medline CASGoogle Scholar
• 48. Raghav N, Sharma MR. Usage of nanocrystalline cellulose phosphate as novel sustained release system for anti-inflammatory drugs. J. Mol. Struct. 1233, 130108 (2021).
  CASGoogle Scholar
• 49. Santos-Martins D, Forli S, Ramos MJ, Olson AJ. AutoDock4Zn: an improved AutoDock force field for small-molecule docking to zinc metalloproteins. J. Chem. Inf. Model. 54(8), 2371–2379 (2014).
  Medline CASGoogle Scholar
• 50. Ravish I, Raghav N. Curcumin as inhibitor of mammalian cathepsin B, cathepsin H, acid phosphatase and alkaline phosphatase: a correlation with pharmacological activities. Med. Chem. Res. 23, 2847–2855 (2014).
  CASGoogle Scholar
• 51. Vats L, Sharma V, Angeli A, Kumar R, Supuran CT, Sharma PK. Synthesis of novel 4-functionalized 1,5-diaryl-1,2,3-triazoles containing benzenesulfonamide moiety as carbonic anhydrase I, II, IV and IX inhibitors. Eur. J. Med. Chem. 150, 678–686 (2018).
  Medline CASGoogle Scholar
• 52. Tanc M, Carta F, Scozzafava A, Supuran CT. 6-Substituted 1, 2-benzoxathiine-2, 2-dioxides are isoform-selective inhibitors of human carbonic anhydrases IX, XII and VA. Org. Biomol. Chem. 13(1), 77–80 (2015).
  Medline CASGoogle Scholar
• 53. Pacchiano F, Carta F, Mcdonald PC et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 54(6), 1896–1902 (2011).
  Medline CASGoogle Scholar
• 54. Saroha B, Kumar G, Kumar S et al. Ultrasound assisted a one pot multicomponent and greener synthesis of 1,2,3-triazole incorporated aurone hybrids: cathepsin B inhibition, anti-cancer activity against AGS cell line, and in-silico docking evaluation. Curr. Res. Green Sustain. Chem. 5, 100295 (2022).
  CASGoogle Scholar
• 55. Cáceres EL, Tudor M, Cheng AC. Deep learning approaches in predicting ADMET properties. Future Med. Chem. 12(22), 1995–1999 (2020).
  CASGoogle Scholar
• 56. Xiong G, Wu Z, Yi J et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49(W1), W5–W14 (2021).
  Medline CASGoogle Scholar
• 57. Yadav CK, Basavaraju M, Mussuvir Pasha KM, Samuel J, Nandeshwarappa BP. Benzothiazole-hydrazone chromophores: synthesis, solvatochromism, computational and antimycobacterial activity studies. ChemistrySelect 8(28), e202301432 (2023).
  Google Scholar
• 58. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46(W1), W257–W263 (2018).
  Medline CASGoogle Scholar
• 59. Mishra A, Dixit S, Ratan V, Srivastava M, Trivedi S, Srivastava YK. Identification and in silico screening of biologically active secondary metabolites isolated from Trichoderma harzianum. Ann. Phytomed. 7(1), 78–86 (2018).
  CASGoogle Scholar
• 60. Molinspiration Cheminformatics Free Web Services. www.molinspiration.com/cgi-bin/properties
  Google Scholar
• 61. Felicetti T, Massari S. Protein–protein interactions by influenza polymerase subunits as drug targets. Future Med. Chem. 14(2), 53–56 (2022).
  CASGoogle Scholar
• 62. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2. 0: new docking methods, expanded force field, and Python bindings. J. Chem. Inf. Model. 61(8), 3891–3898 (2021).
  Medline CASGoogle Scholar